Agency Information Collection Activities; Proposed Collection; Comment Request; Data to Support Food and Nutrition Product Communications, as Used by the Food and Drug Administration, 82030-82031 [2010-32739]
Download as PDF
<![CDATA[
82030
Federal Register / Vol. 75, No. 249 / Wednesday, December 29, 2010 / Notices
on the Internet at https://www.gsa.gov/
ftr. This process, implemented in FTR
Amendment 2010–07 (75 FR 72965,
Nov. 29, 2010), ensures more timely
updates in mileage reimbursement rates
by GSA for Federal employees on
official travel. Notices published
periodically in the Federal Register,
such as this one, and the changes posted
on the GSA Web site, now constitute the
only notification of revisions to
privately owned vehicle reimbursement
rates for Federal agencies.
single-spaced typedpages in length and must
be received by January 21, 2011.
The agenda is subject to change as
priorities dictate.
Contact Person for More Information:
Virginia S. Cain, PhD, Director of Extramural
Research, NCHS/CDC, 3311 Toledo Road,
Room 7211, Hyattsville, Maryland 20782,
telephone (301) 458–4500, fax (301) 458–
4020.
BILLING CODE 6820–14–P
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and othercommittee
management activities, for both the
Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: December 21, 2010.
Elaine L. Baker,
Management Analysis and Services Office,
Centers for Disease Control and Prevention.
Dated: December 21, 2010.
Janet Dobbs,
Acting Deputy Associate Administrator.
[FR Doc. 2010–32773 Filed 12–28–10; 8:45 am]
[FR Doc. 2010–32747 Filed 12–28–10; 8:45 am]
Centers for Disease Control and
Prevention
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
srobinson on DSKHWCL6B1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC), NCHS
announces the following meeting of the
aforementioned committee:
Times and Dates: 11 a.m.–5:30 p.m.,
January 27, 2011. 8:30 a.m.–2 p.m., January
28, 2011.
Place: NCHS Headquarters, 3311 Toledo
Road, Hyattsville, Maryland 20782.
Status: This meeting is open to the public;
however, visitors must be processed in
accordance with established federal policies
and procedures. Pre-approval is required for
foreign nationals or non-US citizens. Please
contact Althelia Harris, 301–458–4261,
adw1@cdc.gov or Virginia Cain,
vcain@cdc.gov at least 10 days in advance for
requirements. All visitors are required to
present a valid form of picture identification
issued by a State, Federal or international
government. The meeting room
accommodates approximately 100 people.
Purpose: This committee provides advice
and makes recommendations to the
Secretary, HHS; the Director, CDC; and the
Director, NCHS, regarding the scientific and
technical program goals and objectives,
strategies, and priorities of NCHS.
Matters to be Discussed: The agenda will
include welcome remarks by the Director,
NCHS; an update on the Health Indicators
Warehouse; an update on program reviews;
and an open session for comments from the
public.
Requests to make oral presentations should
be submitted in writing to the contact person
listed below. All requests must contain the
name, address, telephone number, and
organizational affiliation of the presenter.
Written comments should not exceed five
02:10 Dec 29, 2010
Jkt 223001
Submit either electronic or
written comments on the collection of
information by February 28, 2011.
DATES:
Submit electronic
comments on the collection of
information to https://
www.regulations.gov. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, 301–796–
3793.
Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined in
44 U.S.C. 3502(3) and 5 CFR 1320.3(c)
and includes Agency requests or
requirements that members of the public
submit reports, keep records, or provide
information to a third party. Section
3506(c)(2)(A) of the PRA (44 U.S.C.
3506(c)(2)(A)) requires Federal Agencies
to provide a 60-day notice in the
Federal Register concerning each
proposed collection of information
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
SUPPLEMENTARY INFORMATION:
Board of Scientific Counselors,
National Center for Health Statistics
(BSC, NCHS)
VerDate Mar<15>2010
online sales of food products, and
consumer and professional education.
Food and Drug Administration
[Docket No. FDA–2010–N–0640]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Data to Support
Food and Nutrition Product
Communications, as Used by the Food
and Drug Administration
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the Agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal Agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
a generic clearance to collect
information to support communications
about nutrition and food products
regulated by FDA. This data collection
will gauge, informally, public opinion
on a variety of subjects related to
consumer, patient, or health care
professional perceptions and use of
nutrition and food products and related
materials, including but not limited to,
food advertising, food and nutrition
labeling, emerging risk communications,
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
E:\FR\FM\29DEN1.SGM
29DEN1
82031
Federal Register / Vol. 75, No. 249 / Wednesday, December 29, 2010 / Notices
Data to Support Food and Nutrition
Product Communications, as Used by
the Food and Drug Administration—21
U.S.C. 393(d)(2)(D) (OMB Control
Number 0910–NEW)
FDA plans to use the data collected
under this generic clearance to inform
its nutrition and foods communications
campaigns. FDA expects the data to
guide the formulation of its food and
nutrition communication objectives.
FDA also plans to use the data to help
tailor print, broadcast, and use
electronic media communications in
order for them to have powerful and
desired impacts on target audiences.
The data will not be used for the
purposes of making policy or regulatory
decisions.
The information collected will serve
two major purposes. First, as formative
research, it will provide the critical
knowledge needed about target
audiences. FDA must explore
audiences’ beliefs, perceptions, and
decisionmaking processes about
nutrition and food consumption in
order to formulate the basic objectives of
its risk communication campaigns. Such
knowledge will provide the needed
target audience understanding to design
effective communication strategies,
messages, and product labels. These
communications will aim to improve
public understanding of the risks and
benefits of consuming certain foods or
nutritional products by providing users
with a better context in which to place
risk information more completely.
Second, as initial testing, it will give
FDA some information about the
potential effectiveness of messages and
materials in reaching and successfully
communicating with their intended
audiences. Testing messages with a
sample of the target audience will allow
FDA to refine messages while still in the
developmental stage. Respondents may
be asked to give their reaction to the
messages in individual or group
settings.
FDA’s Center of Food Safety and
Applied Nutrition, Office of the
Commissioner, and other Centers or
Offices will use this mechanism to test
messages about regulated food and
nutrition products on a variety of
subjects related to consumer, patient, or
health care professional perceptions and
use of foods and related materials,
including but not limited to, food
advertising, food and nutrition labeling,
emerging risk communications, online
sales of food products, and consumer
and professional education. The data
will not be used for the purposes of
making policy or regulatory decisions.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
Annual
frequency
per response
Number of
respondents
Total
annual
responses
Hours per
response
Total
hours
Individual indepth interviews ............................................................
General public focus group interviews ............................................
Intercept interviews: central location ...............................................
Intercept interviews: telephone ........................................................
Self-administered surveys ................................................................
Gatekeeper reviews .........................................................................
Omnibus surveys .............................................................................
360
144
600
10,000 2
2,400
400
2,400
1
1
1
1
1
1
1
360
144
600
10,000
2,400
400
2,400
0.75
1.5
0.25
0.08
0.25
0.50
0.17
270
216
150
800
600
200
408
Total (general public) ................................................................
16,304
........................
16,304
........................
2,644
Total physician focus group interviews ....................................
144
1
144
1.5
216
Total (overall) ............................................................................
........................
........................
........................
........................
2,860
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
2 Brief interviews with callers to test messages, concepts and strategies following their call-in request to an FDA Center 1–800 number.
Annually, FDA projects about 30
communication studies using the
variety of test methods listed in table 1.
FDA is requesting this burden so as not
to restrict the Agency’s ability to gather
information on public sentiment for its
proposals in its regulatory and
communications programs.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: December 22, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
AGENCY:
[FR Doc. 2010–32739 Filed 12–28–10; 8:45 am]
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: PulmonaryAllergy Drugs Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
srobinson on DSKHWCL6B1PROD with NOTICES
BILLING CODE 4160–01–P
VerDate Mar<15>2010
02:10 Dec 29, 2010
Jkt 223001
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Pulmonary-Allergy Drugs Advisory
Committee; Notice of Meeting
Food and Drug Administration,
HHS.
ACTION:
PO 00000
Notice.
Frm 00067
Fmt 4703
Sfmt 4703
Date and Time: The meeting will be
held on March 8, 2011, from 8 a.m. to
5 p.m.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room,
(rm. 1503), Silver Spring, MD 20993–
0002. Information regarding special
accommodations due to a disability,
visitor parking and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘White Oak Conference Center
Parking and Transportation Information
for FDA Advisory Committee Meetings.’’
Please note that visitors to the White
Oak Campus must enter through Bldg 1.
Contact Person: Kristine T. Khuc,
Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave, Bldg. 31, rm. 2417, Silver Spring,
E:\FR\FM\29DEN1.SGM
29DEN1
]]>Agencies
[Federal Register Volume 75, Number 249 (Wednesday, December 29, 2010)]
[Notices]
[Pages 82030-82031]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-32739]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0640]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Data to Support Food and Nutrition Product
Communications, as Used by the Food and Drug Administration
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information and
to allow 60 days for public comment in response to the notice. This
notice solicits comments on a generic clearance to collect information
to support communications about nutrition and food products regulated
by FDA. This data collection will gauge, informally, public opinion on
a variety of subjects related to consumer, patient, or health care
professional perceptions and use of nutrition and food products and
related materials, including but not limited to, food advertising, food
and nutrition labeling, emerging risk communications, online sales of
food products, and consumer and professional education.
DATES: Submit either electronic or written comments on the collection
of information by February 28, 2011.
ADDRESSES: Submit electronic comments on the collection of information
to https://www.regulations.gov. Submit written comments on the
collection of information to the Division of Dockets Management (HFA-
305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-3793.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information before
submitting the collection to OMB for approval. To comply with this
requirement, FDA is publishing notice of the proposed collection of
information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
[[Page 82031]]
Data to Support Food and Nutrition Product Communications, as Used by
the Food and Drug Administration--21 U.S.C. 393(d)(2)(D) (OMB Control
Number 0910-NEW)
FDA plans to use the data collected under this generic clearance to
inform its nutrition and foods communications campaigns. FDA expects
the data to guide the formulation of its food and nutrition
communication objectives. FDA also plans to use the data to help tailor
print, broadcast, and use electronic media communications in order for
them to have powerful and desired impacts on target audiences. The data
will not be used for the purposes of making policy or regulatory
decisions.
The information collected will serve two major purposes. First, as
formative research, it will provide the critical knowledge needed about
target audiences. FDA must explore audiences' beliefs, perceptions, and
decisionmaking processes about nutrition and food consumption in order
to formulate the basic objectives of its risk communication campaigns.
Such knowledge will provide the needed target audience understanding to
design effective communication strategies, messages, and product
labels. These communications will aim to improve public understanding
of the risks and benefits of consuming certain foods or nutritional
products by providing users with a better context in which to place
risk information more completely.
Second, as initial testing, it will give FDA some information about
the potential effectiveness of messages and materials in reaching and
successfully communicating with their intended audiences. Testing
messages with a sample of the target audience will allow FDA to refine
messages while still in the developmental stage. Respondents may be
asked to give their reaction to the messages in individual or group
settings.
FDA's Center of Food Safety and Applied Nutrition, Office of the
Commissioner, and other Centers or Offices will use this mechanism to
test messages about regulated food and nutrition products on a variety
of subjects related to consumer, patient, or health care professional
perceptions and use of foods and related materials, including but not
limited to, food advertising, food and nutrition labeling, emerging
risk communications, online sales of food products, and consumer and
professional education. The data will not be used for the purposes of
making policy or regulatory decisions.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Annual
Number of frequency per Total annual Hours per Total
respondents response responses response hours
----------------------------------------------------------------------------------------------------------------
Individual indepth interviews.......... 360 1 360 0.75 270
General public focus group interviews.. 144 1 144 1.5 216
Intercept interviews: central location. 600 1 600 0.25 150
Intercept interviews: telephone........ 10,000 \2\ 1 10,000 0.08 800
Self-administered surveys.............. 2,400 1 2,400 0.25 600
Gatekeeper reviews..................... 400 1 400 0.50 200
Omnibus surveys........................ 2,400 1 2,400 0.17 408
------------------------------------------------------------------------
Total (general public)............. 16,304 .............. 16,304 .............. 2,644
------------------------------------------------------------------------
Total physician focus group 144 1 144 1.5 216
interviews........................
------------------------------------------------------------------------
Total (overall).................... .............. .............. .............. .............. 2,860
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ Brief interviews with callers to test messages, concepts and strategies following their call-in request to
an FDA Center 1-800 number.
Annually, FDA projects about 30 communication studies using the
variety of test methods listed in table 1. FDA is requesting this
burden so as not to restrict the Agency's ability to gather information
on public sentiment for its proposals in its regulatory and
communications programs.
Dated: December 22, 2010.
Leslie Kux,
Acting Assistant Commissioner for Policy.
[FR Doc. 2010-32739 Filed 12-28-10; 8:45 am]
BILLING CODE 4160-01-P
